FDA Fast Tracks ImmVira's Oncolytic Herpes Simplex Virus Therapy for Head and Neck Squamous Cell Cancer

MVR-T3011 IT is in development to treat patients with recurrent or metastatic head and neck squamous cell cancer whose disease progressed following platinum-based chemotherapy and at least one prior line of a PD-1/PD-L1 therapy.

Source link
#FDA #Fast #Tracks #ImmVira039s #Oncolytic #Herpes #Simplex #Virus #Therapy #Neck #Squamous #Cell #Cancer